Michael Gelband’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Michael Gelband’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-442	Closed	-$69K	–	2781
2021 Q4	$69K	Buy	442 +12	+3%	+$2.32K	﹤0.01%	2004
2021 Q3	$86K	Buy	+430	New	+$102K	﹤0.01%	1924
2021 Q2	–	Sell	-626	Closed	-$166K	–	2932
2021 Q1	$166K	Buy	+626	New	+$197K	﹤0.01%	1905
2019 Q2	–	Sell	-1,294	Closed	-$543K	–	1387
2019 Q1	$543K	Buy	1,294 +814	+170%	+$327K	0.04%	306
2018 Q4	$146K	Buy	+480	New	+$155K	0.01%	295

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's EIGR Position: Q1 2022 in Review

Michael Gelband sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 442 shares — an estimated $69K sold.

Michael Gelband first reported a position in EIGR in Q4 2018 and held it in 5 quarters. The position peaked at $543K in Q1 2019. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

Michael Gelband reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Michael Gelband sold 442 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $69K.
Michael Gelband first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
Michael Gelband's Eiger BioPharmaceuticals, Inc. position peaked at $543K in Q1 2019.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.